Avastin Approved For Second-Line CRC
Genentech's Avastin gained approval June 20 for use in second-line treatment of metastatic colorectal cancer as an adjunct to chemotherapy, FDA said
Genentech's Avastin gained approval June 20 for use in second-line treatment of metastatic colorectal cancer as an adjunct to chemotherapy, FDA said